7:55 am Chair’s Opening Remarks

Exploring the Impact of COVID-19 on ARDS Over the Past 12 Months

8:00 am Outlining How the Pandemic Has Transformed the ARDS Drug Development Landscape & Contextualising Key Updates in ARDS Drug Development Over the Past 12 Months


• Exploring the evidence for how complement dysregulation triggers multiple cytokine release and direct tissue damage in pneumonia
• Understanding why the timing of initiation of successful therapy is critically important, ideally with the onset of hypoxia
• The established means of supporting normoxia in self-ventilating patients have been of limited success in avoidance of use of invasive ventilation.

8:30 am Analyzing the Pathology & Molecular Mechanisms Behind COVID-19 Associated ARDS to Determine Which Indicators Best Predict Onset of Severe ARDS & COVID-19 Pneumonia

  • Brijesh Patel Clinical Senior Lecturer in Cardiothoracic, Imperial College London


• Exploring the longitudinal features that determine the onset of severe ARDS & COVID-19 pneumonia using data science and machine learning approaches
• Highlighting the underlying pathophysiological features that determine clinical phenotypes of COVID-19
• Making the jump from clinical observations to mechanisms and molecular targets to modulate the progression and resolution of COVID-19 and non-COVID-19 associated ARDS

9:00 am Panel Discussion: Deep Diving into the Failures of COVID-19 Related ARDS Clinical Trials to Learn How to Avoid Common Mistakes & Streamline the Development of Clinically Effective Therapeutics for COVID-19 ARDS


• Examining lessons learned and outlining how to avoid common mistakes when designing COVID-19 related ARDS clinical trials
• Understanding challenges associate with translating preclinical success into clinical success in the context of ongoing COVID-19 related ARDS clinical trials
• Looking to the future: How to set clear goals and objectives for your clinical trials in 2021

9:30 am Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ARDS drug development field and establish meaningful business relationships to pursue for the rest of the conference.

10:15 am Morning Break & Networking

10:30 am Translating Lessons Learned From COVID-19 Associated ARDS to Non-COVID-19 Associated ARDS: Leveraging the Latest Research to Strategize Drug Development Against ARDS

  • David Thickett Professor of Respiratory Medicine, University of Birmingham


• Understanding: Is COVID ARDS the same as usual ARDS?
• Discussing why COVID 19 immunomodulation has been successful whereas in usual ARDS it has failed so far
• Evaluating the need of post-COVID ARDS platform trials to retest successful therapies in a post-COVID world

Investigating Inflammation in ARDS: What do You Need to Know From a Drug Development Perspective?

11:00 am Elevated Hyaluronan in ARDS Associated With COVID-19

  • Harry Karmouty Assistant Professor, Tenure Track at The University of Texas Health Science Center at Houston (UTHealth)


• What is hyaluronan and what are the potential mechanisms that lead to its up-regulation?

• Identification of increased hyaluronan accumulation in lungs from patients with COVID-19

• Can we inhibit hyaluronan as a treatment for COVID-19- ARDS?

11:30 am Molecular Mechanisms of the ARDS Inflammatory Response in COVID-19 for Drug Development

  • Pablo Pelegrin Scientific Deputy Director & Principal Investigator, Biomedical Research Institute of Murcia


• Understanding inflammasome activation and macrophage activating syndrome in ARDS
• Specifically discussing the role of NLRP3 inflammasome in ARDS by COVID-19
• Hypothesizing the inflammasome as a drug target for ARDS

12:00 pm Targeting Inflammasomes to Control Coronavirus-Induced T cell Dysfunction


• Discovering how TMEM176B is a cation channel that inhibits NLRP3 inflammasomes
• Tmem176b-/- mice showed worse survival and increased viral load upon MHV infection in an inflammasome-dependent manner
• TMEM176B expression was increased in peripheral blood monocytes from mild COVID-19 in comparison to severe patients.
• Pharmacological activation of TMEM176B inhibits SARS-CoV-2-induced inflammasome activation in human monocytes

12:30 pm Lunch & Networking

1:00 pm Audience Discussion: Investigating the Interplay Between the Immune System & the Lungs in Order to Manipulate the Immune Response & Streamline Treatment of Lung Inflammation in ARDS Patients


Exploring the complex relationship between the immune system and lung inflammation from a drug development perspective often leads to a series of tough, seemingly unanswerable questions. How can you manipulate the immune system when treating ARDS but not create auto immunity issues? How do you mitigate the risks of interfering with the immune system? Why do inflammatory drugs not work in COVID 19 ARDS even though they should? Tap into the wealth of knowledge your fellow attendees have on this subject and share your own thoughts on how to decide what the right approach to therapeutics development is at this interactive discursive session.

Uncovering Emerging ARDS Therapies to Maximize Success When Treating ARDS Patients

1:30 pm DAMPening ARDS & VILI Inflammation with a Novel Biologic Targeting eNAMPT

  • Joe Garcia Chief Executive Officer, Aqua Lung Therapeutics


• Understanding the role of DAMPs in driving ARDS mortality and what it means for drug developers
• Revealing the challenges and lessons learned when searching for Novel ARDS Targets- eNAMPT
• Exploring the efficacy of anti-inflammatory mAbs in preclinical ARDS/ VILI models

2:00 pm An Inhaled Inhibitor of MARCKS Improved Oxygenation & Reduced Mortality in ARDS Patients


• Peptide inhibitors of MARCKS block neutrophil migration in response to chemotactic stimuli
• Inhaled peptide inhibitors of MARCKS block neutrophil influx and cytokine production in mouse ARDS models and reverse disease progression
• Reduced mortality and rapid improvement in oxygenation in Phase 2 clinical trial of BIO-11006, an inhibitor of MARCKS

2:30 pm Afternoon Break & Networking

3:00 pm Audience Discussion: Reviewing the Range of Therapies for ARDS Treatment, Considering Their Benefits, Challenges & Clinical Outcomes: Deep Dive Into siRNA, Steroids & JAK Inhibitors


When it comes to treating ARDS, there is no shortage of exciting new therapies to learn more about. What evidence supports the notion that JAK inhibitors are the magic cure-all therapeutic the industry’s been searching for? Can you effectively target siRNA into the cell types needed to reliably treat ARDS? What are the risks involved with using dexamethasone for ARDS? This is your opportunity to benchmark the approaches other attendees are taking to utilizing these emerging therapies and share your own thoughts on siRNAs, steroids and JAK inhibitors in our final, thought-provoking audience discussion of the day.

3:30 pm A Novel Targeted Inhaled Therapy for Treatment of ARDS by Reducing Extravascular Lung Water


• Inhaled route of administration of Solnatide enhances the mechanism of action aimed at reducing extravascular lung water and reducing inflammation
• Clinical data suggests impact on extravascular lung water and corresponding benefits to lung function and ventilator free days
• Solnatide is currently being studied in Covid-19 patients

4:00 pm Evaluating the Risk Reward Profile of Cell Therapies for ARDS and Understanding How They Can be Utilized to Positively Influence Recovery/Mortality in ARDS Patients

  • Racheli Ofir Vice President - Research & IP, Pluristem Therapeutics


  • Reviewing the latest research on cells therapies in the context of ARDS drug development
  •  Outlining the mechanism of action for cell therapies in ARDS treatment
  • Looking to the future: Novel uses of cell therapies for respiratory illness’
  • Considerations of mode of cell administration (IM vs IV)

4:30 pm Therabron (rhCC10 protein): A Host-Targeted Multi-Modal Therapy to Prevent and Treat ARDS

  • Aprile Pilon President & Chief Executive Officer , Trove Therapeutics


• Therabron disrupts inflammatory pathways, preserves lung function, and
promotes pulmonary homeostasis
• Therabron prevents and treats ARDS from multiple causes
• Post-ARDS recovery (e.g. Long COVID): Therabron accelerates repair and
prevents pulmonary fibrosis

5:00 pm GEn1E Lifesciences: A Platform for Advancing Treatments for Rare Inflammatory Diseases

  • Ritu Lal Chief Executive Officer , GEn1E Lifesciences


• GEn1E’s multi-MOA platform of NextGen p38alpha kinase inhibitors
• Lead candidate for therapeutic treatment of ARDS
• Our techbio platform for rapid pipeline development for treatment of
rare inflammatory diseases

5:30 pm End of Day One